Amneal Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 10c, Lowers FY EPS Guidance
November 6, 2019 6:43 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.04, $0.10 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $378.3 million versus the consensus estimate of $408.98 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2019 EPS of $0.31, versus the consensus of... More
